Management of Axillary Lymph Node Found During Revision Surgery for High-Grade Undifferentiated Pleomorphic Sarcoma
Complete axillary lymph node dissection should be performed for this patient, as regional lymph node involvement in soft tissue sarcoma represents stage III disease and requires aggressive surgical management to achieve local control.
Rationale and Approach
Why Axillary Dissection is Indicated
The discovery of an axillary lymph node at the base of a high-grade undifferentiated pleomorphic sarcoma (UPS) tumor cavity is highly significant. While lymph node metastases are uncommon in most soft tissue sarcomas (occurring in <5% of cases), certain histologic subtypes carry higher risk. When nodal involvement is confirmed, complete regional lymph node dissection is the standard of care 1.
Key principle: Regional lymph node clearance should be undertaken if there is evidence of nodal disease, as removal of nodal deposits reduces subsequent problems from ulceration and local complications of secondary tumor deposits 2.
Surgical Management Algorithm
Immediate surgical action:
- Perform complete axillary lymph node dissection (levels I-III)
- The dissection should include tissue inferior to the axillary vein from the latissimus dorsi muscle laterally to the medial border of the pectoralis minor muscle
- Level III dissection to the thoracic inlet should be performed if gross disease is present in level II and/or III 3
Pathologic assessment needed:
- Number of involved lymph nodes
- Presence of extracapsular extension
- Size of nodal metastases
Adjuvant Treatment Considerations
Radiation therapy: Adjuvant radiation to the nodal basin after lymph node dissection is generally recommended for patients with palpable adenopathy, multiple involved lymph nodes, and/or extracapsular extension 4. Given that this is a high-grade (FNCLCC grade 3) UPS with documented nodal involvement, adjuvant radiation to the axilla should be strongly considered.
Systemic therapy: High-grade UPS with nodal metastases represents advanced disease with high risk of distant recurrence. Anthracycline-based chemotherapy (doxorubicin) remains the standard first-line systemic therapy 1, 5. Recent evidence suggests that UPS may be more sensitive to immune checkpoint inhibition compared to other sarcoma subtypes, and combination therapy with checkpoint inhibitors plus doxorubicin has shown promising response rates in recent trials 6, 7.
Staging Workup Required
Before finalizing the treatment plan, complete staging must be performed:
- CT chest: Essential to exclude pulmonary metastases (the most common site of distant spread in soft tissue sarcomas) 8
- CT abdomen/pelvis: Recommended for high-grade sarcomas to assess for visceral metastases 8
- Consider PET-CT: May be valuable before performing radical surgery and provides comprehensive staging in a single study 8
Critical Pitfalls to Avoid
Do not perform sentinel lymph node biopsy alone - Unlike breast cancer where SLNB may be adequate in selected cases, documented nodal involvement in sarcoma requires complete regional dissection 2
Do not delay systemic therapy - High-grade UPS with nodal involvement has poor prognosis; systemic therapy should be initiated promptly after adequate local control is achieved 1, 5
Do not underestimate the infiltrative nature - UPS can have infiltrative growth patterns requiring wider margins than anticipated 5
Multidisciplinary Discussion
This case mandates tumor board discussion including surgical oncology, radiation oncology, and medical oncology to coordinate the sequence of treatments. The presence of nodal disease significantly impacts prognosis and treatment intensity 1.
Expected outcomes: Even with aggressive multimodality treatment, the presence of lymph node metastases in high-grade soft tissue sarcoma portends a guarded prognosis, with median survival typically measured in months to a few years depending on extent of disease and response to systemic therapy 6, 5.